Literature DB >> 15773910

Activation of Akt/PKB, increased phosphorylation of Akt substrates and loss and altered distribution of Akt and PTEN are features of Alzheimer's disease pathology.

Rebecca J Griffin1, Aileen Moloney, Mary Kelliher, Janet A Johnston, Rivka Ravid, Peter Dockery, Rosemary O'Connor, Cora O'Neill.   

Abstract

Studies suggest that activation of phosphoinositide 3-kinase-Akt may protect against neuronal cell death in Alzheimer's disease (AD). Here, however, we provide evidence of increased Akt activation, and hyperphosphorylation of critical Akt substrates in AD brain, which link to AD pathogenesis, suggesting that treatments aiming to activate the pathway in AD need to be considered carefully. A different distribution of Akt and phospho-Akt was detected in AD temporal cortex neurons compared with control neurons, with increased levels of active phosphorylated-Akt in particulate fractions, and significant decreases in Akt levels in AD cytosolic fractions, causing increased activation of Akt (phosphorylated-Akt/total Akt ratio) in AD. In concordance, significant increases in the levels of phosphorylation of total Akt substrates, including: GSK3beta(Ser9), tau(Ser214), mTOR(Ser2448), and decreased levels of the Akt target, p27(kip1), were found in AD temporal cortex compared with controls. A significant loss and altered distribution of the major negative regulator of Akt, PTEN (phosphatase and tensin homologue deleted on chromosome 10), was also detected in AD neurons. Loss of phosphorylated-Akt and PTEN-containing neurons were found in hippocampal CA1 at end stages of AD. Taken together, these results support a potential role for aberrant control of Akt and PTEN signalling in AD.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15773910     DOI: 10.1111/j.1471-4159.2004.02949.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  184 in total

Review 1.  mTOR in health and in sickness.

Authors:  Dritan Liko; Michael N Hall
Journal:  J Mol Med (Berl)       Date:  2015-09-22       Impact factor: 4.599

2.  Regulation of autophagic flux by CHIP.

Authors:  Dongkai Guo; Zheng Ying; Hongfeng Wang; Dong Chen; Feng Gao; Haigang Ren; Guanghui Wang
Journal:  Neurosci Bull       Date:  2015-07-28       Impact factor: 5.203

3.  PTEN recruitment controls synaptic and cognitive function in Alzheimer's models.

Authors:  Shira Knafo; Cristina Sánchez-Puelles; Ernest Palomer; Igotz Delgado; Jonathan E Draffin; Janire Mingo; Tina Wahle; Kanwardeep Kaleka; Liping Mou; Inmaculada Pereda-Perez; Edvin Klosi; Erik B Faber; Heidi M Chapman; Laura Lozano-Montes; Ana Ortega-Molina; Lara Ordóñez-Gutiérrez; Francisco Wandosell; Jose Viña; Carlos G Dotti; Randy A Hall; Rafael Pulido; Nashaat Z Gerges; Andrew M Chan; Mark R Spaller; Manuel Serrano; César Venero; José A Esteban
Journal:  Nat Neurosci       Date:  2016-01-18       Impact factor: 24.884

4.  Insulin Attenuates Beta-Amyloid-Associated Insulin/Akt/EAAT Signaling Perturbations in Human Astrocytes.

Authors:  Xiaojuan Han; Liling Yang; Heng Du; Qinjian Sun; Xiang Wang; Lin Cong; Xiaohui Liu; Ling Yin; Shan Li; Yifeng Du
Journal:  Cell Mol Neurobiol       Date:  2015-09-10       Impact factor: 5.046

Review 5.  The Essential Role of Soluble Aβ Oligomers in Alzheimer's Disease.

Authors:  Zi-Xuan Wang; Lan Tan; Jinyuan Liu; Jin-Tai Yu
Journal:  Mol Neurobiol       Date:  2015-04-02       Impact factor: 5.590

6.  Activation of the Cannabinoid Type 2 Receptor by a Novel Indazole Derivative Normalizes the Survival Pattern of Lymphoblasts from Patients with Late-Onset Alzheimer's Disease.

Authors:  Patricia Del Cerro; Carolina Alquézar; Fernando Bartolomé; Pedro González-Naranjo; Concepción Pérez; Eva Carro; Juan A Páez; Nuria E Campillo; Ángeles Martín-Requero
Journal:  CNS Drugs       Date:  2018-06       Impact factor: 5.749

Review 7.  The nature, significance, and glucagon-like peptide-1 analog treatment of brain insulin resistance in Alzheimer's disease.

Authors:  Konrad Talbot; Hoau-Yan Wang
Journal:  Alzheimers Dement       Date:  2014-02       Impact factor: 21.566

8.  Hippocampal proNGF signaling pathways and β-amyloid levels in mild cognitive impairment and Alzheimer disease.

Authors:  Elliott J Mufson; Bin He; Muhammad Nadeem; Sylvia E Perez; Scott E Counts; Sue Leurgans; Jason Fritz; James Lah; Stephen D Ginsberg; Joanne Wuu; Stephen W Scheff
Journal:  J Neuropathol Exp Neurol       Date:  2012-11       Impact factor: 3.685

Review 9.  AKT/PKB Signaling: Navigating the Network.

Authors:  Brendan D Manning; Alex Toker
Journal:  Cell       Date:  2017-04-20       Impact factor: 41.582

10.  The insulin/Akt signaling pathway is targeted by intracellular beta-amyloid.

Authors:  Han-Kyu Lee; Pravir Kumar; Qinghao Fu; Kenneth M Rosen; Henry W Querfurth
Journal:  Mol Biol Cell       Date:  2009-01-14       Impact factor: 4.138

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.